Brain Tumors in Children
|
|
- Elinor Golden
- 5 years ago
- Views:
Transcription
1 Brain Tumors in Children Michael A. Grotzer University Children s Hospital of Zurich, Switzerland Incidence of Childhood Cancer CNS Tumors Acute lymphoblastic Leukemia Neuroblastoma Non-Hodgkin Lymphoma Wilms Tumor Hodgkin Lymphoma Acute myeloblastic Leukemia Rhabdomyosarcoma Retinoblastoma Osteosarcoma Ewing Sarcoma Others 0% 10% 20%
2 Prognosis of Pediatric Cancer 5-Year Survival Probability 100% 80% 60% 40% 20% Wilms Tumor ALL Osteosarcoma CNS Tumors 0% Years of diagnosis SEER (USA) Etiology of Childhood CNS Tumors: Hereditary Factors NF-1 astrocytomas (optic pathways) NF-2 schwannomas (vestibular, trigeminal), ependymomas, meningiomas Tuberous sclerosis cortical dysplasia (cortical tubers), subependymal nodules, subependymal giant cell astrocytomas Von Hippel-Lindau disease hemangioblastomas (cerebellar, ) Turcot syndrome medulloblastoma NBCC syndrome medulloblastoma Li-Fraumeni syndrome choroid plexus carcinoma, astrocytomas, medulloblastoma, ependymoma
3 Etiology of Childhood CNS Tumors: Ionizing Radiation Cranial irradiation for treatment of tinea capitis, leukemia, CNS tumors Radiation doses as low as 3 Gy Latency usually 5-25 years Most of these secondary CNS tumors classified as astrocytomas and meningiomas Etiology of Childhood CNS Tumors: Other Factors Endogenous immunosuppression Wiskott-Aldrich syndrome Ataxia teleangiektasia Exogenous immunosuppression Organ-transplant recipients HIV infection Polyomaviruses? SV40, JC, BK
4 Pediatric Brain Tumors Differ From Adult Brain Tumors Histology: The types of tumors encountered in children are uncommon in adults, and vice versa Localization: infratentorial > supratentorial Surgery: The value of extensive tumor resection has been confirmed for a variaty of childhood brain tumors Chemotherapy: has been shown to be effective in improving overall outcome in several childhood brain tumors is increasingly used to delay or avoid using radiotherapy in children younger than 3 years of age AT/RT Medulloblastoma Pilocytic Astrocytoma female male Ependymoma Diffuse Astrocytoma WHO II Glioblastoma Age (years)
5 Survival by Age for Malignant Brain Tumors Population Survival Probability Ages 0-19 Ages Ages Ages 60+ Years since diagnosis SEER (USA) Technical Advances in Imaging and Neurosurgery
6 Irradiation Using Protons Protons Photons Energy Photons Distance Protons Ependymoma: Incidence and Epidemiology Frequency: 10-15% of all childhood CNS cancers Prevalence: 1 in 28,000 live birth (USA) Median age: 6 years No known predisposing exposures
7 Ependymoma: Localization Posterior fossa > supratentorial extraventricular > lateral ventricles > spinal The majority of tumors are localized at the time of diagnosis The primary tumor site remains the most likely area of disease relapse Pathology and Grading Ependymoma WHO II Anaplastic Ependymoma WHO III microvascular proliferation high mitotic activity
8 Ependymoma: Prognostic Factors positive negative Total resection Less than total resection Age over 4-6 years Age under 4-6 years Local XRT > 45 Gy Local XRT < 45 Gy Differentiated (WHO II) Anaplastic (WHO III) 6.9 years old, focal seizures
9 Localized Ependymoma >4 Years of Age STOP Surgery: No residual OP no residual tumor tumor Conformal Irradiation WHO II WHO III CP VP16 CP VP16 CP VP16 CP VP16 CP VP16 8 months Merchant TE et al. Lancet Oncol 2009 n=153 median age 2.9 years Conformal radiotherapy (59.4 Gy, 10 mm margin) after definitive surgery
10 0.8 years old, head tilt (5 weeks), vomiting (2 weeks) Localized Ependymoma <4 Years of Age Residual Tumor <15 months OP CP VP16 CP VP16 MTX MTX CP VP16 MTX MTX CP VP16 Protonbeam Irradiation weekly CP VP16 CP VP months 3 months
11 14 months later Irradiation Using Protons Protons Photons Energy Photons Distance Protons
12 Anesthesia
13 Patient immobilization
14 Appropriate patient safety system
15 Medulloblastoma Before Surgery Radio local Chemo 5-Year Survival 0% 0% Since 1940 local + cs 50% Since % 80%
16
17 Medulloblastoma: Treatment for Children > 3 Years (Packer RJ, 1994) S U R G E R Y RADIATION Posterior fossa 54 Gy Craniospinal 36 Gy Cisplatin Lomustine Vincristin week
18 Longterm Effects of Current Medulloblastoma Therapy Growth dysfunction Endocrine dysfunction Hearing loss Alopecia Risk for second malignancies Social and emotional problems Intellectual deficits Late Effects in Pediatric Brain Tumor Survivors: Interplay of Different Factors Therapy Tumor Patient RT total dose direct tissue effects development status RT dose rate RT treatment volume indirect mechanical effects genetic predisposition tissue sensitivities RT dose distribution compensating mechanisms other therapy
19 HIT-SKK`92 Medulloblastoma Age <3 years / hdmtx Carbo/VP / hdmtx Carbo/VP / hdmtx Carbo/VP CCR End of Therapy MTX i. ventr. MTX i. ventr. MTX i. ventr. no CCR <18 Months >18 Months experimental Chemo craniospinal Radiation Rutkowski S et al. N Engl J Med 2005 HIT-SKK` No RT Survival Probability ± ± ± 0.15 no residual tumor residual tumor solid metastases n=17 n=14 n= Years Since Diagnosis Rutkowski S et al. N Engl J Med 2005
20 Intensity-Modulated Radiotherapy (IMRT) 54.2 Gy 64 % auditory apparatus radiation WHO grade 3/4 hearing loss (n = 26 medulloblastoma) 36.7 Gy (-32%) 13 % Huang E et al. Int J Radiat Oncol Biol Phys 2002 Irradiation Using Protons Energy Photons Protons Photons Protons Distance
21 Medulloblastoma Staging: Modified Chang Classification System M1 Tumor cells in CSF M2 Nodular seeding in cerebellum, cerebral subarachnoid space, or in 3 rd or 4 th ventricles M3 Nodular seeding in spinal subarachnoid space M4 Extraneuraxial metastasis Patient Stratification S U R G E R Y Clinical Factors + Molecular Phenotype Low Risk: Minimal Therapy Standard Risk: Maximal Therapy High Risk: Novel Therapies
22 c-myc β-catenin 1.00 Low c-myc (n=13) Progression-free Survival Probability High c-myc (n=13) Overall Survival Probability Nuclear accumulation (n=27) No accumulation (n=81) p= Years Since Diagnosis Grotzer, Clin Cancer Res 2001 p=0.015 Years Since Diagnosis Ellison, J Clin Oncol 2005 Classic MB (64-83%) composed of sheets of small uniform cells with a high nuclear-to cytoplasmatic ratio Anaplastic MB medulloblastoma with extensive nodularity (3%) contains pleomorphic Desmoplastic cells MB with (7%) polyhedral combines forms and nodules a high of differentiated growth neurocytic cells with a low growth fraction. Abundant apoptosis and fraction and desmoplastic internodular examples of cell wrapping are evident zones of moderately pleomorphic cells with a high growth fraction Infants (favourable prognosis) and adults Gilbertson Gilbertson & Ellison & Ellison Annu Annu Rev Pathol Rev Pathol Mech Mech Dis 2008 Dis 2008
23 Nodular/desmoplastic medulloblastoma combines nodules of differentiated neurocytic cells with a low growth fraction and desmoplastic internodular zones of moderately pleomorphic cells with a high growth fraction Anaplastic MB (10-22%) contains pleomorphic cells with polyhedral forms and a high growth fraction. Abundant apoptosis and examples of cell wrapping are evident Large-cell MB (2-4%) contains groups of large uniform cells with vesicular nuclei and a single nucleolus. Anaplasia characterizes other regions of this variant Gilbertson & Ellison Annu Rev Pathol Mech Dis 2008 Localized Medulloblastoma <4 Years of Age HIT 2000 Carbo VP-16 Carbo VP-16 CR + desmoplastic / extensive nodular OP / hdmtx CARBO / VP-16 MTX i. ventr. / hdmtx CARBO / VP-16 MTX i. ventr. / hdmtx CARBO / VP-16 MTX i. ventr. Radiotherapy 54 Gy conformal no CR CIS CCNU CIS CCNU CIS CCNU CIS CCNU <18 months CIS CCNU CIS CCNU CIS CCNU CIS CCNU Radiotherapy 54 Gy conformal
24 Medulloblastoma are molecularly distinct from spnet and AT/RT Pomeroy SL et al. Nature 2002 Atypical Teratoid/Rhabdoid CNS Tumor (AT/RT) Mutation/deletion of the tumor suppressor SMARCB1 (INI1) WHO % Burger P, Am. J Surg Pathol 1998 Number of cases Age (years) female male Survival 80% 60% 40% 20% 0% Months after diagnosis
25 AT/RT Boston Protocol DFCI V: Vincristine P: Cisplatin D: Doxorubicin C: Cyclophosphamide E: Etoposide A: Dactinomycin i.th.: MTX, Cytarabin, Hydrocortisone 2-year Overall Survival: 70 ± 10% Chi S et al. JCO 2008 Unsupervised hierarchical clustering of human 1.0 exon array expression data from 103 primary medulloblastomas using 1,450 high standard deviation genes Northcott P A et al. JCO 2010
26 10% 30% 25% 35% Nuclear β-catenin Oncogenes, Tumor Suppressors, and Key Cytogenetics Northcott PA et al. (2012) Nat. Rev. Neurol.
27 Therapeutic Targets of WNT Medulloblastomas Low risk None of the WNT targeted therapies have shown benefits in MB Therapies that target mutated TP53 are not in regular use for MB therapy Mouse model of WNT MB developed Current strategy: de-escalation not large cell/anaplastic c-myc/mycn not amplified β-catenin nuclear pos. residual tumor 1.5 cm 2 OP Radiotherapy 23.4 Gy craniospinal 54 Gy local PNET5 CIS CCNU CIS CCNU 6 months CIS CCNU Standard risk all others all without profile OP Radiotherapy 23.4 Gy craniospinal 54 Gy local PNET6 CIS CCNU CIS CCNU CIS CCNU CIS CCNU ± CARBOPLATIN 8 months SIOP PNET Study Group Therapeutic Targets of SHH Medulloblastomas GDC-0449 IPI-026 LDE225 <3 years + >14 years of age Desmoplastic / nodular subtype Somatic mutations in PTCH1/2, SMO, or SUFU High-level amplification of the SHH effectors, GLI1/2 Germline mutations of SUFU (young children), PTCH1 (Gorlin syndrome) SMO antagonists GDC-0449, IPI-926, LDE225,
28 SMO Inhibitor Treatment in an Adult with Metastatic MB Rudin CM et al. N Engl J Med 2009 after 2 months of therapy with GDC-0449 after 5 months of therapy with GCD-0449 SMO Inhibitor Treatment in an Adult with Metastatic MB Rudin CM et al. N Engl J Med 2009 after 2 months of therapy with GDC-0449 after 5 months of therapy with GCD-0449
29 SMO Inhibitor Treatment in an Adult with Metastatic MB Rudin CM et al. N Engl J Med 2009 after 2 months of therapy with GDC-0449 after 5 months of therapy with GCD-0449 Hh activation Pre Screening TMZ naive children and adults who have relapsed after RT (n=69) TMZ pretreated children and adults who have relapsed after RT OR RT naive ± TMZ children 6 years old (n=40) Randomization 2:1 LDE225 QD TMZ, QD x 5 every 28 days LDE225 QD LDE225 QD Optional Cross-over to LDE225 QD confirmed PD Post Treatment FollowUp Primary endpoints: ORR Secondary endpoints: DoR, PFS, safety, OS, QoL
30 LDE225 (200 mg QD): Responses in Medulloblastoma Pre-treatment: surgery, irradiation, 4 chemotherapy regimens and HDCT Partial response maintained for 4 months Therapeutic Targets of Group 3 Medulloblastomas Owing the pharmacological difficulty of targeting a a transcription factor, small molecule inhibitors of MYC have not yet achieved wide success or acceptance in the clinic Studies on other rationally chosen targets for Group 3 have not yet been described Mouse model available Current strategy: intensification Therapeutic Targets of Group 4 Medulloblastomas The underlying biology of Group 4 tumors is less well understood Mouse model not yet available Current strategy:??
31 MB Metastases and Primary Tumors are Distinct XH Wu et al. Nature 2012 Conclusions Patient subgroup status will become an integral component of prospective clinical trials This will enable the use of treatment protocols that are rationally tailored towards each subgroup of the disease Methods to verify patient subgroup affiliation will continue to evolve Targeting primary tumor targeting metastasis
Tumors of the Nervous System
Tumors of the Nervous System Peter Canoll MD. PhD. What I want to cover What are the most common types of brain tumors? Who gets them? How do they present? What do they look like? How do they behave? 1
More informationCNS pathology Third year medical students. Dr Heyam Awad 2018 Lecture 12: CNS tumours 2/3
CNS pathology Third year medical students Dr Heyam Awad 2018 Lecture 12: CNS tumours 2/3 Pilocytic astrocytoma Relatively benign ( WHO grade 1) Occurs in children and young adults Mostly: in the cerebellum
More informationTARGET THERAPY IN NON GLIOMA BRAIN TUMORS.
TARGET THERAPY IN NON GLIOMA BRAIN TUMORS. Meduloblastoma and Sonic Hedgehog inhibitor Jordi Rodon Ana Garrido TARGET THERAPY IN NON GLIOMA BRAIN TUMORS. Meduloblastoma and Sonic Hedgehog inhibitor Medulloblastoma
More informationPeter Canoll MD. PhD.
Tumors of the Nervous System Peter Canoll MD. PhD. What I want to cover What are the most common types of brain tumors? Who gets them? How do they ypresent? What do they look like? How do they behave?
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM MEDULLOBLASTOMA AND PNET CNS Site Group Medulloblastoma and PNET Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2. PREVENTION
More informationCNS TUMORS. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)
CNS TUMORS D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) CNS TUMORS The annual incidence of intracranial tumors of the CNS ISmore than intraspinal tumors May be Primary or Secondary
More information7/1/2015. Radiotherapy in Infant Brain Tumors. Goals and Objectives. Primary Brain and CNS Tumors (0-14 years) Brain Tumors (1 to 4 years)
Radiotherapy in Infant Brain Tumors ARNOLD C. PAULINO, M.D. PROFESSOR OF RADIATION ONCOLOGY MD ANDERSON CANCER CENTER AND TEXAS CHILDREN S HOSPITAL Radiotherapy in Infant Brain Tumors 1. Try to Avoid Irradiation
More informationPediatric Oncology. Vlad Radulescu, MD
Pediatric Oncology Vlad Radulescu, MD Objectives Review the epidemiology of childhood cancer Discuss the presenting signs and symptoms, general treatment principles and overall prognosis of the most common
More informationSYSTEMIC MANAGEMENT OF PEDIATRIC PRIMARY BRAIN TUMORS
SYSTEMIC MANAGEMENT OF PEDIATRIC PRIMARY BRAIN TUMORS María E. Echevarría, MD Assistant Professor University of Puerto Rico Medical Sciences Campus DISCLOSURES No disclosures INTRODUCTION Pediatric CNS
More informationAdvances in Brain Tumor Research: Leveraging BIG data for BIG discoveries
Advances in Brain Tumor Research: Leveraging BIG data for BIG discoveries Jill Barnholtz-Sloan, PhD Associate Professor & Associate Director for Bioinformatics and Translational Informatics jsb42@case.edu
More informationCase 1. Maysa Al-Hussaini MD FRCPath
Case 1 Maysa Al-Hussaini MD FRCPath MAYSA King AL-HUSSAINI Hussein Cancer MD Center MRCPATH KING HUSSEIN Amman CANCER Jordan CENTER Clinical history 4 year old boy History of frontal headache, sleepiness.
More informationSOLID TUMOURS IN CHILDHOOD
SOLID TUMOURS IN CHILDHOOD Fareed Omar Paediatric Oncology Steve Biko Academic hospital Introduction 1 Introduction Lymphomas and Leukemias make up about 40% of all childhood Cancers (Systemic cancers)
More informationSupra- and infratentorial brain tumors from childhood to maternity
Supra- and infratentorial brain tumors from childhood to maternity What to expect? I am going to show you the characteristic imaging findings of following tumors: Thierry A.G.M. Huisman, MD, FICIS, EQNR
More informationPediatric Brain Tumors: Updates in Treatment and Care
Pediatric Brain Tumors: Updates in Treatment and Care Writer Classroom Rishi R. Lulla, MD MS Objectives Introduce the common pediatric brain tumors Discuss current treatment strategies for pediatric brain
More informationBrain tumors are, as a group, the most common
See the corresponding editorial in this issue, pp 133 134. J Neurosurg Pediatrics 8:000 000, 8:135 148, 2011 Multidisciplinary management of childhood brain tumors: a review of outcomes, recent advances,
More informationProtocol Abstract and Schema
Protocol Abstract and Schema A Phase I Trial of p28 (NSC745104), a Non-HDM2 mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive CNS tumors Description and
More informationUpdate on Pediatric Brain Tumors
Update on Pediatric Brain Tumors David I. Sandberg, M.D. Director of Pediatric Neurosurgery & Associate Professor Dr. Marnie Rose Professorship in Pediatric Neurosurgery Pre-talk Questions for Audience
More informationThe treatment of childhood cancer is one of the great
A Review of Secondary Central Nervous System Tumors After Treatment of a Primary Pediatric Malignancy Asher M. Marks, MD,* and Roger J. Packer, MD,,, Despite remarkable strides in the treatment of pediatric
More informationCURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of 4/27/2017)
CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of 4/27/2017) Leukemia AALL0932 closed after Induction Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized
More informationCHAPTER 11 Tumors Originating in the Brain Medulloblastomas, PNETs and Ependymomas
Tumors Originating in the Brain Medulloblastomas, PNETs and Ependymomas Foolishly, I waited 7 months before I joined this (or any) group. By that time, my son had radiation, chemo, and a recurrence of
More information7/1/2015. Objectives. Host Factors LATE EFFECTS OF RADIOTHERAPY IN CHILDHOOD CANCER. Chronic Conditions in Adult Survivors
LATE EFFECTS OF RADIOTHERAPY IN CHILDHOOD CANCER ARNOLD C. PAULINO, M.D. PROFESSOR DEPARTMENT OF RADIATION ONCOLOGY MD ANDERSON CANCER CENTER Objectives At the end of the presentation, the participant
More informationChildhood Brain and Spinal Cord Tumors Treatment Overview (PDQ )
1 di 8 04/03/2017 07.31 NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute
More information-Proton Beam Therapy in Paediatric Radiation Oncology -
-Proton Beam Therapy in Paediatric Radiation Oncology - Beate Timmermann, M.D. West German Proton Therapy Centre Essen Germany Preview Survival Toxicity Why protons? (theoretically) Experiences so far
More informationMedulloblastoma / high risk. Radiotherapy in high risk medulloblastoma
Radiotherapy in high risk medulloblastoma PROS Meeting London 4.-6. October 2012 Reference Centre for Radiotherapy, Dept. for Radiation Oncology University of Leipzig Johannisallee 34, 04107 Leipzig/Germany
More information21/03/2017. Disclosure. Practice Changing Articles in Neuro Oncology for 2016/17. Gliomas. Objectives. Gliomas. No conflicts to declare
Practice Changing Articles in Neuro Oncology for 2016/17 Disclosure No conflicts to declare Frances Cusano, BScPharm, ACPR April 21, 2017 Objectives Gliomas To describe the patient selection, methodology
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cns_embryonal_tumors
More informationNeuro-oncology Update Andrew Kokkino, MD Medical Director, The Neurosciences Institute at Sacred Heart at Riverbend May 20, 2013
Neuro-oncology Update 2013 Andrew Kokkino, MD Medical Director, The Neurosciences Institute at Sacred Heart at Riverbend May 20, 2013 Case 1 58 year old man with recent facial droop and HA s Thin, cachectic
More informationPediatric Medulloblastoma: Molecular biology, correlation with histopathological and clinical outcome
Pediatric Medulloblastoma: Molecular biology, correlation with histopathological and clinical outcome Submitted for MCh Neurosurgery By Dr. Amit Kumar Upadhyay October 2014 Department of Neurosurgery Sree
More informationJournal of Pediatric Sciences
Journal of Pediatric Sciences Role of post-operative radiation therapy in single brain metastasis from clear cell sarcoma in children: a case report with systemic review Fadoua Rais, Naoual Benhmidou,
More informationPediatric CNS Tumors. Disclosures. Acknowledgements. Introduction. Introduction. Posterior Fossa Tumors. Whitney Finke, MD
Pediatric CNS Tumors Disclosures Whitney Finke, MD Neuroradiology Fellow PGY-6 University of Utah Health Sciences Center Salt Lake City, Utah None Acknowledgements Introduction Nicholas A. Koontz, MD Luke
More informationExploring the potential for clinical introduction of hippocampal-sparing IMPT of pediatric medulloblastoma - Past present and future
Exploring the potential for clinical introduction of hippocampal-sparing IMPT of pediatric medulloblastoma - Past present and future Daniel Gasic Disclosure Nothing to disclose Introduction Background
More informationNew Imaging Concepts in Central Nervous System Neoplasms
New Imaging Concepts in Central Nervous System Neoplasms Maarten Lequin Department of Pediatric Radiology Wilhelmina Children s Hospital/University Medical Center Utrecht New Imaging Concepts in Central
More informationSmall and Big Operations: New Tools of the Trade for Brain Tumors. Disclosure. Incidence of Childhood Cancer
Small and Big Operations: New Tools of the Trade for Brain Tumors Nalin Gupta MD PhD Chief, Division of Pediatric Neurosurgery Departments of Neurosurgery and Pediatrics University of California San Francisco
More informationCHILDHOOD CANCER SURVIVOR STUDY ANALYSIS CONCEPT PROPOSAL
CHILDHOOD CANCER SURVIVOR STUDY ANALYSIS CONCEPT PROPOSAL 1. Study title: Subsequent neoplasms among survivors of childhood cancer not previously treated with radiation 2. Working group and investigators:
More informationDiagnostic application of SNParrays to brain cancers
Diagnostic application of SNParrays to brain cancers Adriana Olar 4/17/2018 No disclosures 55 yo M, focal motor seizure T2 T1-post C DIAGNOSIS BRAIN, LEFT FRONTAL LOBE, BIOPSY: - DIFFUSE GLIOMA, OLIGODENDROGLIAL
More informationBRAIN TUMORS IN INFANTS
BRAIN TUMORS IN INFANTS Dr Sergio Valenzuela M.D-( ISPN-ESPN-FLANC)&cols. Head Pediatric Neurosurgery Unit I Instituto de NeurocirugiaAsenjo Santiago CHILE RATE OF MENINGEAL,BRAIN AND OTHER CNS MALIGNANT
More informationPediatr Blood Cancer 2014
Low grade Glioma! 40% of pediatric brain tumors Pathologically, anatomically, clinically and biologically heterogeneous Leptomeningeal metastases in 5% Frequently protracted clinical course Long-Term Outcome
More informationA PROSPECTIVE RANDOMISED CONTROLLED TRIAL OF HYPERFRACTIONATED VERSUS CONVENTIONALLY FRACTIONATED RADIOTHERAPY IN STANDARD RISK MEDULLOBLASTOMA
A PROSPECTIVE RANDOMISED CONTROLLED TRIAL OF HYPERFRACTIONATED VERSUS CONVENTIONALLY FRACTIONATED RADIOTHERAPY IN STANDARD RISK MEDULLOBLASTOMA HIT SIOP PNET 4 A SIOP and GPOH TRIAL START DATE 1 st September
More informationProceedings of Congress
HK J Paediatr (new series) 2012;17:123-129 Proceedings of Congress 2011 Annual Scientific Meeting: Hong Kong Paediatric Haematology and Oncology Study Group 26 March 2011 Acute Lymphoblastic Leukaemia
More informationState of the Art Radiotherapy for Pediatric Tumors. Suzanne L. Wolden, MD Memorial Sloan-Kettering Cancer Center
State of the Art Radiotherapy for Pediatric Tumors Suzanne L. Wolden, MD Memorial Sloan-Kettering Cancer Center Introduction Progress and success in pediatric oncology Examples of low-tech and high-tech
More informationNon-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)
Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Lymphoid Neoplasms: 1- non-hodgkin lymphomas (NHLs) 2- Hodgkin lymphoma 3- plasma cell neoplasms Non-Hodgkin lymphomas (NHLs) Acute Lymphoblastic Leukemia/Lymphoma
More informationIntracranial AT RT / radiotherapy. Therapeutic dilemma / radiotherapy
Therapeutic dilemma / radiotherapy Agressive tumour, poor outcome Past treatments based on MB concepts (RT CSA) MB Overall survival Mean age : 6.52 years n=36, 5 year 75% 1. Tumour occurs in the very young
More informationHIT-MED Guidance for Patients with newly diagnosed Medulloblastoma Ependymoma CNS Embryonal Tumour * and Pineoblastoma
HIT-MED Guidance for Patients with newly diagnosed Medulloblastoma Ependymoma CNS Embryonal Tumour * and Pineoblastoma Version 4.0 Attention: The guidance given here describes current treatment strategies
More informationDr.Dafalla Ahmed Babiker Jazan University
Dr.Dafalla Ahmed Babiker Jazan University Brain tumors are the second commonest malignancy in children Infratentorial tumors are more common As a general rule they do not metastasize out of the CNS, but
More informationACR TXIT TM EXAM OUTLINE
ACR TXIT TM EXAM OUTLINE Major Domain Sub-Domain 1 Statistics 1.1 Study design 1.2 Definitions of statistical terms 1.3 General interpretation & analysis 1.4 Survival curves 1.5 Specificity/sensitivity
More informationGeneral: Brain tumors are lesions that have mass effect distorting the normal tissue and often result in increased intracranial pressure.
1 Lecture Objectives Know the histologic features of the most common tumors of the CNS. Know the differences in behavior of the different tumor types. Be aware of the treatment modalities in the various
More informationOncological Management of Brain Tumours. Anna Maria Shiarli SpR in Clinical Oncology 15 th July 2013
Oncological Management of Brain Tumours Anna Maria Shiarli SpR in Clinical Oncology 15 th July 2013 Outline General considerations of Primary Brain Tumours: epidemiology, pathology, presentation. Diagnosis
More informationEffective local and systemic therapy is necessary for the cure of Ewing tumor Most chemotherapy regimens are a combination of cyclophosphamide,
Ewing Tumor Perez Ewing tumor is the second most common primary tumor of bone in childhood, and also occurs in soft tissues Ewing tumor is uncommon before 8 years of age and after 25 years of age In the
More informationUPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS
UPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS Antonio M. Omuro Department of Neurology Memorial Sloan-Kettering Cancer Center II International Neuro-Oncology Congress Sao Paulo, 08/17/12 CHALLENGES IN
More informationBrain tumors: tumor types
Brain tumors: tumor types Tumor types There are more than 120 types of brain tumors. Today, most medical institutions use the World Health Organization (WHO) classification system to identify brain tumors.
More informationPediatrics -Proton Beam Therapy in Children -
Pediatrics -Proton Beam Therapy in Children - Beate Timmermann, M.D. West German Proton Therapy Centre Essen Germany Preview Survival Toxicity Why protons? (theoretically) Experiences so far (clinically)
More informationOncogenes and Tumor Suppressors MCB 5068 November 12, 2013 Jason Weber
Oncogenes and Tumor Suppressors MCB 5068 November 12, 2013 Jason Weber jweber@dom.wustl.edu Oncogenes & Cancer DNA Tumor Viruses Simian Virus 40 p300 prb p53 Large T Antigen Human Adenovirus p300 E1A
More informationNodule Formation and Desmoplasia in Medulloblastomas Defining the Nodular/Desmoplastic Variant and Its Biological Behavior
RESEARCH ARTICLE DOI 10.1111/j.1750-3639.2007.00058.x Nodule Formation and Desmoplasia in Medulloblastomas Defining the Nodular/Desmoplastic Variant and Its Biological Behavior Charles S. McManamy 1,2
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More information11/27/2017. Proton Therapy for Brain Tumors: Hope or Hype? Financial Disclosures. Objectives. None
Proton Therapy for Brain Tumors: Hope or Hype? 1 Financial Disclosures None 2 Objectives Discuss the rationale and evidence for proton therapy in children and adults Discuss the late effects that can be
More informationHematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma
Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma Policy Number: Original Effective Date: MM.07.013 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 02/24/2012
More informationCOG-ACNS1422: A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Page 1 of 5 COG-ACNS1422: A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients FAST FACTS Eligibility Reviewed and Verified By MD/DO/RN/LPN/CRA Date MD/DO/RN/LPN/CRA
More informationShared Care & Survival CTYA SSCRG (Childhood Cancer Research Group)
Shared Care & Survival CTYA SSCRG (Childhood Cancer Research Group) January 2013 The NCIN is a UK-wide initiative, working to drive improvements in standards of cancer care and clinical outcomes by improving
More informationSTUDY OFPAEDIATRIC CNS TUMORS IN TERTIARY CARE CENTER
IJCRR Section: Healthcare Sci. Journal Impact Factor 4.016 Original Article STUDY OFPAEDIATRIC CNS TUMORS IN TERTIARY CARE CENTER Grishma P. Jobanputra Tutor, Department of Pathology, B.J. Medical College,
More informationRational targeting of very high-risk medulloblastoma of childhood - 1 st progress report
Rational targeting of very high-risk medulloblastoma of childhood - 1 st progress report year Purpose of the research Medulloblastoma is the most common malignant brain tumor of childhood and treatments
More informationNON-SURGICAL STRATEGY FOR ADULT EPENDYMOMA
NON-SURGICAL STRATEGY FOR ADULT EPENDYMOMA Roberta Rudà Department of Neuro-Oncology University and City of Health and Science Hospital of Turin, Italy EORTC EANO ESMO Conference 2015 Istanbul, March 27-28
More informationAlleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen?
Department of Radiation Oncology Chairman: Prof. Dr. Matthias Guckenberger Alleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen? Matthias
More informationCCSS Concept Proposal Working Group: Biostatistics and Epidemiology
Draft date: June 26, 2010 CCSS Concept Proposal Working Group: Biostatistics and Epidemiology Title: Conditional Survival in Pediatric Malignancies: A Comparison of CCSS and SEER Data Proposed Investigators:
More informationIntroduction to Pediatric Neoplasms
Introduction to Pediatric Neoplasms F C D S E D U C A T I O N A L W E B C A S T S E R I E S S T E V E N P E A C E, B S, C T R / M A Y R A E S P I N O, B A, R H I T, C T R J A N U A R Y 1 7, 2 0 1 3 1 Program
More informationSystemic Treatment. Third International Neuro-Oncology Course. 23 May 2014
Low-Grade Astrocytoma of the CNS: Systemic Treatment Third International Neuro-Oncology Course São Paulo, Brazil 23 May 2014 John de Groot, MD Associate Professor, Neuro-Oncology UT MD Anderson Cancer
More information1/15/2013. Introduction to Pediatric Neoplasms. Program Outline. Introduction
Introduction to Pediatric Neoplasms F C D S E D U C A TI O N A L WE B C A S T S E R I E S ST E VE N P E A C E, B S, C T R / MA Y R A E SP I N O, B A, R H I T, C T R J A N U A R Y 1 7, 2 0 1 3 1 Program
More informationPROCARBAZINE, lomustine, and vincristine (PCV) is
RAPID PUBLICATION Procarbazine, Lomustine, and Vincristine () Chemotherapy for Anaplastic Astrocytoma: A Retrospective Review of Radiation Therapy Oncology Group Protocols Comparing Survival With Carmustine
More informationWe are IntechOpen, the first native scientific publisher of Open Access books. International authors and editors. Our authors are among the TOP 1%
We are IntechOpen, the first native scientific publisher of Open Access books 3,350 108,000 1.7 M Open access books available International authors and editors Downloads Our authors are among the 151 Countries
More informationBone & soft tissue sarcoma Central nervous sytem tumors. Dr.Lövey József
Bone & soft tissue sarcoma Central nervous sytem tumors Dr.Lövey József Bone tumors Very rare (0,8 / 100 000) Osteogenic tumors Etiology Metaphysis Radiation Chemicals? Rare genetic syndroms Histology
More informationPET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationChemotherapy for Childhood Medulloblastoma and Primitive Neuroectodermal Tumors
Chemotherapy for Childhood and Primitive Neuroectodermal Tumors ROGER J. PACKER, a JONATHAN L. FINLAY b a Department of Neurology, Children s National Medical Center, Washington DC, USA; b Departments
More informationLeptomeningeal Carcinomatosis: Risks, Detection, and Treatment. Goldie Kurtz, MD, FRCPC Department of Radiation Oncology University of Pennsylvania
Leptomeningeal Carcinomatosis: Risks, Detection, and Treatment Goldie Kurtz, MD, FRCPC Department of Radiation Oncology University of Pennsylvania May 13, 2016 Disclosures None to declare 2 Outline Epidemiology
More informationCarol Marquez, M.D. Department of Radiation Medicine OHSU
Carol Marquez, M.D. Department of Radiation Medicine OHSU JL is a 8 year old boy who presented with coordination problems in using his right hand (difficulty tying his shoes) in January 2011. Imaging revealed
More informationCase Report Tackling a Recurrent Pinealoblastoma
Case Reports in Oncological Medicine, Article ID 135435, 4 pages http://dx.doi.org/10.1155/2014/135435 Case Report Tackling a Recurrent Pinealoblastoma Siddanna Palled, 1 Sruthi Kalavagunta, 1 Jaipal Beerappa
More informationProspective Trial for the Diagnosis and Treatment of Intracranial Germ Cell Tumors (SIOPCNSGCTII)
1 von 9 10.12.2013 09:03 A service of the U.S. National Institutes of Health Trial record 1 of 1 for: UKM08_0057 Previous Study Return to List Next Study Prospective Trial for the Diagnosis and Treatment
More informationBackground. Paediatric cancer. Leukaemia
66 9. Paediatric cancer Background Radiotherapy (RT) is an important modality of therapy in the local control of paediatric malignancies and the majority of paediatric tumours are radiosensitive. However,
More informationDiffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma (DLBCL) DLBCL/MCL Dr. Anthea Peters, MD, FRCPC University of Alberta/Cross Cancer Institute Disclosures Honoraria from Janssen, Abbvie, Roche, Lundbeck, Seattle Genetics Objectives
More informationPEDIATRIC ORBITAL TUMORS RADIOTHERAPY PLANNING
PEDIATRIC ORBITAL TUMORS RADIOTHERAPY PLANNING ANATOMY ANATOMY CONT ANATOMY CONT. ANATOMY CONT. EYE OF A CHILD Normal tissue tolerance doses (in conventional #) TD 5/5 TD 50/5 Endpoint Gy Gy Optic nerve
More informationMedical Late Effects of Childhood Cancer
Medical Late Effects of Childhood Cancer Robert Goldsby Associate Professor of Clinical Pediatric UCSF Late Mortality in 5+ Year Survivors 1.00 US Female US Male Survival function estimate 0.70 0.75 0.80
More informationRole of Prophylactic Cranial Irradiation in Small Cell Lung Cancer
Role of Prophylactic Cranial Irradiation in Small Cell Lung Cancer Kazi S. Manir MD,DNB,ECMO,PDCR Clinical Tutor Department of Radiotherapy R. G. Kar Medical College and Hospital, Kolkata SCLC 15% of lung
More informationProton Therapy for Ependymoma and Craniopharyngioma at the University of Florida: Lessons Learned About Efficacy and Toxicity
Proton Therapy for Ependymoma and Craniopharyngioma at the University of Florida: Lessons Learned About Efficacy and Toxicity Danny Indelicato, MD Mendenhall Chair of Pediatric Radiotherapy University
More informationProphylactic Cranial Irradiation in Acute Lymphoblastic Leukemia: Is there still an indication? Celine Bicquart, MD Radiation Medicine May 5, 2010
Prophylactic Cranial Irradiation in Acute Lymphoblastic Leukemia: Is there still an indication? Celine Bicquart, MD Radiation Medicine May 5, 2010 Outline Epidemiology Risk-groups Background & Rationale
More informationChildhood Cancer Survivor Study Analysis Concept Proposal
Childhood Cancer Survivor Study Analysis Concept Proposal Title: Neurologic and Neurosensory Adverse Sequelae in Long-term Survivors of Childhood Brain Tumors: An Update and Expanded Risk Factor Analysis
More informationContemporary Management of Glioblastoma
Contemporary Management of Glioblastoma Incidence Rates of Primary Brain Tumors Central Brain Tumor Registry of the United States, 1992-1997 100 Number of Cases per 100,000 Population 10 1 0.1 x I x I
More informationTest Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar
Link full download:https://getbooksolutions.com/download/test-bank-for-robbinsand-cotran-pathologic-basis-of-disease-9th-edition-by-kumar Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th
More informationGlioblastoma: Current Treatment Approach 8/20/2018
Glioblastoma: Current Treatment Approach 8/20/2018 Overview What is Glioblastoma? How is it diagnosed How is it treated? Principles of Treatment Surgery, Radiation, Chemotherapy Current Standard of care
More informationUpdate on Sarcomas of the Head and Neck. Kevin Harrington
Update on Sarcomas of the Head and Neck Kevin Harrington Overview Classification and incidence of sarcomas Clinical presentation Challenges to treatment Management approaches Prognostic factors Radiation-induced
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationPathologic Analysis of CNS Surgical Specimens
2015 Kenneth M. Earle Memorial Neuropathology Review Pathologic Analysis of CNS Surgical Specimens Peter C. Burger, MD Interdisciplinary Quality Control Familiarity with entities Use of diagnostic algorithm
More informationSecond Neoplasms Working Group. CCSS Investigators Meeting June 2017
Second Neoplasms Working Group CCSS Investigators Meeting June 2017 Second Neoplasms Working Group Overview Ongoing review, adjudication and entry of reported neoplasms into data set Initial review of
More informationNCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) BONE (Version , 03/28/18)
BONE (Version 2.2018, 03/28/18) NCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) Radiation Therapy Specialized techniques such as intensity-modulated RT (IMRT); particle beam RT with protons, carbon ions,
More informationAMERICAN BRAIN TUMOR ASSOCIATION. Medulloblastoma
AMERICAN BRAIN TUMOR ASSOCIATION Medulloblastoma ACKNOWLEDGEMENTS ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit
More informationHigh grade glioma + brainstem glioma
+ brainstem glioma Highly agressive tumours Median survival ca 9-12 months Curative or palliative treatments? Intensity of treatment Side effects Quality of life issues + brainstem glioma Aims of radiotherapy
More informationavailable at journal homepage:
E U R O P E A N J O U R NA L O F CA N C E R46 (21) 12 133 available at www.sciencedirect.com journal homepage: www.ejconline.com Primary postoperative chemotherapy without radiotherapy for treatment of
More informationCase Report Antiangiogenic Therapy in the Treatment of Recurrent Medulloblastoma in the Adult: Case Report and Review of the Literature
Oncology Volume 2009, Article ID 247873, 4 pages doi:10.1155/2009/247873 Case Report Antiangiogenic Therapy in the Treatment of Recurrent Medulloblastoma in the Adult: Case Report and Review of the Literature
More informationTumors of the Central Nervous System
Tumors of the Central Nervous System 1 Financial Disclosures I have NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT Introduction General: Brain tumors are lesions that have mass effect
More informationESMO DOUBLE-HIT LYMPHOMAS
ESMO DOUBLE-HIT LYMPHOMAS Professor Dr. med. Georg Lenz Director Department of Hematology and Oncology Universitätsklinikum Münster, Germany OVERVIEW Definition of double-hit lymphomas Introduction in
More informationTUMORS of nervous system
TUMORS of nervous system By: Shifaa Alqa qa Done By : Ola Hijjawi CNS tumors : The annual incidence of CNS tumors ranges from 10 to 17 per 100,000 persons for intracranial tumors and 1 to 2 per 100,000
More informationDr Sneha Shah Tata Memorial Hospital, Mumbai.
Dr Sneha Shah Tata Memorial Hospital, Mumbai. Topics covered Lymphomas including Burkitts Pediatric solid tumors (non CNS) Musculoskeletal Ewings & osteosarcoma. Neuroblastomas Nasopharyngeal carcinomas
More informationChildhood Liver Tumours The SIOPEL experience. Giorgio Perilongo, Clinica Pediatrica, Dipartimento A.I. Di Pediatria di Padova
Childhood Liver Tumours The SIOPEL experience Giorgio Perilongo, Clinica Pediatrica, Dipartimento A.I. Di Pediatria di Padova On behalf of the International Childhood Liver Tumour Strategy Group - SIOPEL
More information